AbbVie: Arthritis, Rheumatoid trials

The registry lists 77 Arthritis, Rheumatoid studies with AbbVie as lead sponsor. 5 are open to participants now and 53 have results posted.

Phase 1 6Phase 2 16Phase 3 12Phase 4 4No phase 40(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)RecruitingNCT07607964Phase 1
• A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisRecruitingNCT06972446Phase 2
• A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)RecruitingNCT06917742Phase 1
• A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGRecruitingNCT06712628
• Expanded Access to UpadacitinibAvailableNCT04159597
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)TerminatedNCT04888585Phase 2Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)CompletedNCT03823391Phase 2Results posted
• A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibTerminatedNCT03823378Phase 2Results posted
• A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisCompletedNCT03682705Phase 2Results posted
• A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT03086343Phase 3Results posted
• A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)CompletedNCT02955212Phase 3Results posted
• Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)CompletedNCT02750800Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsCompletedNCT02720523Phase 2/3Results posted
• A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)CompletedNCT02706951Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateCompletedNCT02706873Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT02706847Phase 3Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneCompletedNCT02675426Phase 3Results posted
• Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in ChinaCompletedNCT02668640Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateActive, not recruitingNCT02629159Phase 3Results posted
• Real-World Outcome of Rheumatoid Arthritis Patients in Korea on AdalimumabCompletedNCT02627924Results posted
• Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in TaiwanCompletedNCT02616380Results posted
• Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 StudyCompletedNCT02433340Phase 2Results posted
• A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) SubjectsCompletedNCT02198651Phase 4Results posted
• A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedNCT02141997Phase 2Results posted
• A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX AloneCompletedNCT02066389Phase 2Results posted
• An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid ArthritisCompletedNCT02049138Phase 2Results posted
• A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyCompletedNCT01960855Phase 2Results posted
• Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological AgentsCompletedNCT01783730Results posted
• Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian PopulationTerminatedNCT01782469Results posted
• Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical PracticeCompletedNCT01768858Results posted
• Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical PracticeCompletedNCT01756235Results posted
• Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With AdalimumabCompletedNCT01752855Phase 2Results posted
• Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical PracticeCompletedNCT01736189Results posted
• A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and SafetyCompletedNCT01712178Phase 2Results posted
• Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.CompletedNCT01561313Phase 2Results posted
• A Crossover Study of the Safety and Tolerability of Two Formulations of AdalimumabCompletedNCT01502423Phase 2Results posted
• A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in MalaysiaCompletedNCT01387789Results posted
• Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)CompletedNCT01383421Results posted
• Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069CompletedNCT01346501Results posted
• Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)CompletedNCT01346488Results posted
• Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With AdalimumabCompletedNCT01282372Results posted
• Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With AdalimumabCompletedNCT01273519Results posted
• Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)CompletedNCT01185301Phase 3Results posted
• A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)CompletedNCT01185288Phase 4Results posted
• The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis PatientsCompletedNCT01163617Phase 2Results posted
• Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid ArthritisCompletedNCT01163318Results posted
• Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))CompletedNCT01163292Results posted
• A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid ArthritisCompletedNCT01162421Phase 4Results posted
• Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRACompletedNCT01117480Results posted
• A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in GreeceCompletedNCT01086033Results posted
• A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )CompletedNCT01078558Results posted
• EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European CountriesCompletedNCT01078402Results posted
• Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid ArthritisCompletedNCT01078155Results posted
• Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical PracticeCompletedNCT01078090Results posted
• Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical PracticeCompletedNCT01077258Results posted
• Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid ArthritisCompletedNCT01076205Results posted
• A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical RemissionCompletedNCT00808509Phase 4Results posted
• Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid ArthritisCompletedNCT00195663Phase 3Results posted
• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT05814627Phase 3
• An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World PracticeCompletedNCT05327920
• An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid ArthritisCompletedNCT05170646
• A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT04574492
• A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisCompletedNCT04541810
• A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid ArthritisCompletedNCT04497597
• Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsCompletedNCT04340115
• An Observational Study to Evaluate Impact of CRP-Level on Real World Effectiveness of Upadacitinib as Monotherapy or in Combination With MTX in Adult Participants With Rheumatoid ArthritisCompletedNCT04267536
• Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory DiseasesCompletedNCT03339089
• Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health ServiceCompletedNCT03223012
• Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to MethotrexateWithdrawnNCT02786563
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid ArthritisCompletedNCT02531178Phase 1
• Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid ArthritisCompletedNCT02362074
• Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRAWithdrawnNCT02322723
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid ArthritisCompletedNCT01853033Phase 1
• A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494CompletedNCT01741493Phase 1
• A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RACompletedNCT01078597
• Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid ArthritisCompletedNCT00650156Phase 1
• Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye SyndromeCompletedNCT00025818Phase 3